For life sciences companies focused on rare diseases, accurate patient finding is a worthy challenge—one deserving dedicated time and resource to tackling and solving. The benefit of enrolling even one new patient is large, both for the lives of…
An analysis was conducted of all the orphan therapies registered by the FDA and ANVISA before and after 2018 to effectively evaluate approval times once the RDC 205 pathway was implemented. The main takeaways from the analysis can be found below [...]
Executive Summary While 7 additional rare disease drugs were included on the 2020 NRDL in China, this development comes amid a backdrop of rare disease policy development signaling a move towards multi-channel funding mechanism to support more widespread patient…